Biomarkers for hepatocellular cancer

doi:10.4254/wjh.v12.i9.558

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8299)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

594

WORD

204

HTML

5396

Figures (1-4)

266

Tables (1-2)

186

Sum=6646

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

634

Download

1019

Sum=1653

Sep 27, 2020 (publication date) through Apr 16, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Sep 27, 2020; 12(9): 558-573
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.558

Open in New Tab Full Size Figure Download Figure

Figure 1 The development of hepatocellular carcinoma is recognized to occur through intermediate steps involving inflammation or fibrosis (cirrhosis) via a variety of mechanisms. NASH: Non-alcoholic steatohepatitis; TERT: Telomerase reverse transcriptase; CTNNB1: Catenin beta 1; TP53: Tumor protein 53; CDKN2: Cyclin-dependent kinase inhibitor 2A; ARID1A: AT-Rich Interaction Domain 1A; ARID2A: AT-Rich Interaction Domain 2A; VEGFA: Vascular endothelial growth factor A; FGF19: Fibroblast growth factor 19; CNND1: Cyclin D1; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Formula 1

Open in New Tab Full Size Figure Download Figure

Formula 2

Open in New Tab Full Size Figure Download Figure

Figure 2 Markers associated with cancer development and those associated with response to surgical intervention or chemotherapy. HCC: Hepatocellular carcinoma; AFP-L3: Isoform of AFP binding lectin L3; DCP: Des-gamma carboxyprothrombin; AKBR1B0: Aldo-keto reductase family 1 member 10; SALL4: Sal-like protein 4; GALAD: Gender, Age: Lens culinaris agglutinin-reactive of alpha-fetoprotein, Alpha-fetoprotein, and Des-γ-carboxy prothrombin.

Citation: Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573
URL: https://www.wjgnet.com/1948-5182/full/v12/i9/558.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i9.558